Research
Scientists at Bath Cancer Research undertake ex vivo drug sensitivity
studies using the TRAC assay (Tumour Response to Anti-neoplastic Compounds,
a development of the DiSC assay [Ref. 10 of Selected
Publications]). With this we assess the cytotoxic drug sensitivity
of fresh human cells from patients with leukaemia and lymphoma. Our greatest
expertise is with chronic lymphocytic leukaemia (CLL), acute myeloid leukaemia
(AML or ANLL), non-Hodgkin's lymphoma (NHL) and similar diseases. More info
Service
Bath Cancer Research provides consultant haematologists/ oncologists an
international service for the diseases above. Cells from their patients
are tested for ex vivo drug response to a panel of cytotoxic drugs (up
to 25 drugs). A report is sent to the physician to aid choice of optimum
therapy. This information helps maximise the likelihood of response (and
therefore survival) and reduces the risk of causing patient toxicity with
no clinical benefit. Some assays are chargeable. More info
Funding
The work of Bath Cancer Research is funded by grants, contracts, sale
of services and donations. It does not receive any money from the NHS or the government. It is a local charity with an international brief. It has benefits greatly from the support of the local community for which we are thankful. More info
Latest news
Dr Bosanquet presents his work at a symposium in Reykjavik, Iceland (30th March 2008) with colleagues on the latest advances in ITRT (Individualised Tumor Response testing).
Director: Dr Andrew G Bosanquet
BSc PhD MRCPath CChem FRSC
Wolfson Centre, Royal United Hospital, Bath, BA1 3NG, UK
Tel: +44 (0) 1225 824 124 ... Fax: +44 (0) 1225 824 114
Suggestions, comments and queries for Bath Cancer
Research
© Bath Cancer Research 2000-2008
Date last modified: 26/3/08.
Webmaster: webmaster@caltri.org
|
For
Patients